

Certificate of Analysis for NR-51585

Pseudomonas aeruginosa, Strain MRSN 16744

Catalog No. NR-51585

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 16744 was isolated in 2013 from human tissue as part of a surveillance program in the United States. P. aeruginosa, strain MRSN 16744 was deposited as sensitive to amikacin, cefepime, ceftazidime, ciprofloxacin, gentamicin, levofloxacin, piperacillin/tazobactam and tobramycin, intermediately resistance to aztreonam and resistant to imipenem and meropenem.

Lot: 70025076¹ Manufacturing Date: 17JUL2019

TEST SPECIFICATIONS RESULTS Phenotypic Analysis Gram-negative rods Gram-negative rods Colony morphology² Report results Circular, slightly peaked, undu smooth and cream (Figure 1 worth should be smooth and cream (Figure 2 worth should be smooth and cream (Figure 3 worth should be smooth and cream (
Cellular morphology² Gram-negative rods Gram-negative rods Colony morphology² Report results Circular, slightly peaked, undu smooth and cream (Figure ² Motility (wet mount) Report results Motile VITEK® 2 (GN card) P. aeruginosa (≥ 89%) P. aeruginosa (97%) Antibiotic Susceptibility Profile³ VITEK® (AST-GN81 Card) Report results Resistant (≥ 32 μg/mL) Amoxicillin/clavulanic acid Report results Resistant (≥ 84 μg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 μg/mL) Cefazolin Report results Resistant (≥ 64 μg/mL) Cefoxitin Report results Resistant (≥ 64 μg/mL) Ceftazidime Sensitive Sensitive (4 μg/mL) Ceftriaxone Report results Resistant (16 μg/mL) Cefepime Sensitive Sensitive (4 μg/mL) Meropenem Resistant Resistant (8 μg/mL) Amikacin Sensitive Sensitive (≤ 2 μg/mL) Gentamicin Sensitive Sensitive (≤ 1 μg/mL) Tobramycin Sensitive Sensitive (≤ 1 μg/mL) Ciprofloxacin Sensitive Sensitive (≤ 0.25 μg/mL)<			
Colony morphology² Report results Circular, slightly peaked, undus smooth and cream (Figure 1 Motile yITEK® 2 (GN card) Circular, slightly peaked, undus smooth and cream (Figure 1 Motile yITEK® 2 (GN card) Antibiotic Susceptibility Profile³ P. aeruginosa (≥ 89%) P. aeruginosa (97%) VITEK® (AST-GN81 Card) Report results Resistant (≥ 32 μg/mL) Ampicillin Report results Resistant (≥ 32 μg/mL) Ampicillin/clavulanic acid Report results Resistant (≥ 64 μg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 μg/mL) Cefazolin Report results Resistant (≥ 64 μg/mL) Cefazidime Sensitive Sensitive (4 μg/mL) Ceftazidime Sensitive Sensitive (≥ 4 μg/mL) Cefepime Sensitive Sensitive (≥ μg/mL) Meropenem Resistant Resistant (8 μg/mL) Amikacin Sensitive Sensitive (≥ 1 μg/mL) Gentamicin Sensitive Sensitive (≤ 1 μg/mL) Tobramycin Sensitive Sensitive (≤ 1 μg/mL) Ciprofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Tetracycline Report results Resistant (≥ 16 μg/mL) Nitrofurantoin			
Motility (wet mount) Report results Motile Motile P. aeruginosa (97%) Antibiotic Susceptibility Profile³ VITEK® (AST-GN81 Card) Ampicillin Report results Resistant (≥ 32 µg/mL) Amoxicillin/clavulanic acid Report results Resistant (≥ 32 µg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 µg/mL) Cefazolin Report results Resistant (≥ 64 µg/mL) Cefoxitin Report results Resistant (≥ 64 µg/mL) Ceftriaxone Sensitive Sensitive (4 µg/mL) Cefepime Sensitive Sensitive (2 µg/mL) Meropenem Resistant Resistant (16 µg/mL) Amikacin Sensitive Sensitive (2 µg/mL) Gentamicin Sensitive Sensitive (≤ 2 µg/mL) Tobramycin Sensitive Sensitive (≤ 1 µg/mL) Ciprofloxacin Sensitive Sensitive (≤ 0.25 µg/mL) Levofloxacin Sensitive Sensitive (≤ 0.25 µg/mL) Tetracycline Report results Resistant (≥ 61 µg/mL) Nitrofurantoin Report results Resistant (≥ 6 µg/mL) Resistant (≥ 6 µg/mL)			
VITEK® 2 (GN card) P. aeruginosa (≥ 89%) P. aeruginosa (97%) Antibiotic Susceptibility Profile³ VITEK® (AST-GN81 Card) Ampicillin Report results Resistant (≥ 32 μg/mL) Amoxicillin/clavulanic acid Report results Resistant (≥ 64 μg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 μg/mL) Cefazolin Report results Resistant (≥ 64 μg/mL) Cefoxitin Report results Resistant (≥ 64 μg/mL) Ceftazidime Sensitive Sensitive (4 μg/mL) Cefepime Sensitive Sensitive (2 μg/mL) Meropenem Resistant Resistant (16 μg/mL) Amikacin Sensitive Sensitive (2 μg/mL) Gentamicin Sensitive Sensitive (≤ 1 μg/mL) Tobramycin Sensitive Sensitive (≤ 1 μg/mL) Ciprofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Levofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Tetracycline Report results Resistant (≥ 16 μg/mL) Nitrofurantoin Report results Resistant (≥ 160 μg/mL) Trimethoprim/sulfamethoxazole ≥ 99% sequence identity to 99.9% sequence ident			
VITEK® 2 (GN card) P. aeruginosa (≥ 89%) P. aeruginosa (97%) Antibiotic Susceptibility Profile³ VITEK® (AST-GN81 Card) Ampicillin Report results Resistant (≥ 32 μg/mL) Amoxicillin/clavulanic acid Report results Resistant (≥ 64 μg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 μg/mL) Cefazolin Report results Resistant (≥ 64 μg/mL) Cefoxitin Report results Resistant (≥ 64 μg/mL) Ceftriaxone Sensitive Sensitive (4 μg/mL) Cefepime Sensitive Sensitive (2 μg/mL) Meropenem Resistant Resistant (16 μg/mL) Amikacin Sensitive Sensitive (≤ 2 μg/mL) Gentamicin Sensitive Sensitive (≤ 2 μg/mL) Tobramycin Sensitive Sensitive (≤ 1 μg/mL) Ciprofloxacin Sensitive Sensitive (≤ 1 μg/mL) Levofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Tetracycline Report results Resistant (≥ 610 μg/mL) Nitrofurantoin Report results Resistant (≥ 610 μg/mL) Trimethoprim/sulfamethoxazole ≥ 99% sequence identity to 99.9% sequence ident			
VITEK® (AST-GN81 Card) Report results Resistant (≥ 32 μg/mL) Amoxicillin/clavulanic acid Report results Resistant (≥ 32 μg/mL) Piperacillin/tazobactam Sensitive Sensitive (8 μg/mL) Cefazolin Report results Resistant (≥ 64 μg/mL) Cefoxitin Report results Resistant (≥ 64 μg/mL) Ceftazidime Sensitive Sensitive (4 μg/mL) Ceftriaxone Report results Resistant (16 μg/mL) Cefepime Sensitive Sensitive (2 μg/mL) Meropenem Resistant Resistant (8 μg/mL) Amikacin Sensitive Sensitive (≤ 2 μg/mL) Gentamicin Sensitive Sensitive (≤ 2 μg/mL) Tobramycin Sensitive Sensitive (≤ 1 μg/mL) Ciprofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Levofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Tetracycline Report results Resistant (≥ 16 μg/mL) Nitrofurantoin Report results Resistant (≥ 16 μg/mL) Resistant (≥ 512 μg/mL) Report results ≥ 160 μg/mL ⁴			
Amoxicillin/clavulanic acidReport resultsResistant (≥ 32 μg/mL)Piperacillin/tazobactamSensitiveSensitive (8 μg/mL)CefazolinReport resultsResistant (≥ 64 μg/mL)CefoxitinReport resultsResistant (≥ 64 μg/mL)CeftazidimeSensitiveSensitive (4 μg/mL)CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
Piperacillin/tazobactamSensitiveSensitive (8 μg/mL)CefazolinReport resultsResistant (≥ 64 μg/mL)CefoxitinReport resultsResistant (≥ 64 μg/mL)CeftazidimeSensitiveSensitive (4 μg/mL)CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
Piperacillin/tazobactamSensitiveSensitive (8 μg/mL)CefazolinReport resultsResistant (≥ 64 μg/mL)CefoxitinReport resultsResistant (≥ 64 μg/mL)CeftazidimeSensitiveSensitive (4 μg/mL)CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
CefoxitinReport resultsResistant (≥ 64 μg/mL)CeftazidimeSensitiveSensitive (4 μg/mL)CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
CeftazidimeSensitiveSensitive (4 μg/mL)CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
CeftriaxoneReport resultsResistant (16 μg/mL)CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
CefepimeSensitiveSensitive (2 μg/mL)MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
MeropenemResistantResistant (8 μg/mL)AmikacinSensitiveSensitive (≤ 2 μg/mL)GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
Amikacin Sensitive Sensitive $(\le 2 \mu g/mL)$ Gentamicin Sensitive Sensitive $(\le 1 \mu g/mL)$ Tobramycin Sensitive Sensitive Sensitive $(\le 1 \mu g/mL)$ Ciprofloxacin Sensitive Sensitive Sensitive $(\le 0.25 \mu g/mL)$ Levofloxacin Sensitive Sensitive Sensitive $(\le 0.25 \mu g/mL)$ Tetracycline Report results Resistant $(\ge 16 \mu g/mL)$ Nitrofurantoin Report results Resistant $(\ge 512 \mu g/mL)$ Trimethoprim/sulfamethoxazole Report results $(\ge 160 \mu g/mL)$ Senotypic Analysis Sequencing of 16S ribosomal RNA gene $(\ge 99\%)$ sequence identity to $(\le 2 \mu g/mL)$ Sensitive $(\le 2 \mu g/mL)$ Sensitive $(\le 1 \mu g/mL)$ Resistant $(\ge 512 \mu g/mL)$ Report results $(\ge 160 \mu g/mL)$ Senotypic Analysis Sequence identity to $(\ge 99.9\%)$ sequence identity to			
GentamicinSensitiveSensitive (≤ 1 μg/mL)TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
TobramycinSensitiveSensitive (≤ 1 μg/mL)CiprofloxacinSensitiveSensitive (≤ 0.25 μg/mL)LevofloxacinSensitiveSensitive (≤ 0.25 μg/mL)TetracyclineReport resultsResistant (≥ 16 μg/mL)NitrofurantoinReport resultsResistant (≥ 512 μg/mL)Trimethoprim/sulfamethoxazoleReport results≥ 160 μg/mL⁴Genotypic AnalysisSequencing of 16S ribosomal RNA gene≥ 99% sequence identity to99.9% sequence identity to			
Ciprofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Levofloxacin Sensitive Sensitive (≤ 0.25 μg/mL) Tetracycline Report results Resistant (≥ 16 μg/mL) Nitrofurantoin Report results Resistant (≥ 512 μg/mL) Trimethoprim/sulfamethoxazole Report results ≥ 160 μg/mL⁴ Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Levofloxacin Sensitive Sensitive Sensitive (≤ 0.25 μ g/mL) Tetracycline Nitrofurantoin Report results Report results Resistant (≥ 16 μ g/mL) Resistant (≥ 512 μ g/mL) Trimethoprim/sulfamethoxazole Report results Report results ≥ 160 μ g/mL ⁴ Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Tetracycline Report results Resistant (≥ 16 μg/mL) Nitrofurantoin Report results Resistant (≥ 512 μg/mL) Trimethoprim/sulfamethoxazole Report results ≥ 160 μg/mL⁴ Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Nitrofurantoin Report results Resistant (≥ 512 μg/mL) Trimethoprim/sulfamethoxazole Report results ≥ 160 μg/mL⁴ Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Trimethoprim/sulfamethoxazole Report results ≥ 160 μg/mL⁴ Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Genotypic Analysis Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
Sequencing of 16S ribosomal RNA gene ≥ 99% sequence identity to 99.9% sequence identity to			
(~ 1470 hase nairs) P. seruginosa strain MRSN 16744 P. seruginosa strain MRSN			
(GenBank: RXVO01000053.1) (GenBank: RXVO01000053.1)			
Purity (post-freeze) ⁵ Growth consistent with expected colony morphology Growth consistent with expected colony morphology	ted		
Viability (post-freeze) ² Growth Growth			

¹NR-51585 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)


⁴Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa.*" <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.

⁵Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.



Certificate of Analysis for NR-51585

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

13 DEC 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898